# MET

2 EU-approved indications of 2 drugs need a MET result, in 1 tumour type, most of them in non-small cell lung cancer.

## Approved indications by tumour

### Non-small cell lung cancer

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Capmatinib](https://oncolabels.com/drugs/capmatinib) (Tabrecta) | Alterations leading to METex14 skipping | Monotherapy | 2nd line, advanced | After prior treatment with immunotherapy and/or platinum-based chemotherapy |
| [Tepotinib](https://oncolabels.com/drugs/tepotinib) (Tepmetko) | Leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping | Monotherapy | 2nd line, advanced | After prior treatment with immunotherapy and/or platinum-based chemotherapy |

## Label wording

- **Tepotinib** (Tepmetko), Non-small cell lung cancer, 2nd line, advanced: “TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf)
- **Capmatinib** (Tabrecta), Non-small cell lung cancer, 2nd line, advanced: “Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/met